Companies / Atlas Bio
Atlas Bio
Switzerland
Atlas Bio runs in silico clinical trials in immunology using its foundation AI model of human biology to predict and compare patient responses across treatments and indications
Atlas Bio, based in Switzerland, has 2 investors on file, among them Creandum and First Momentum. Its latest round on record is Pre-Seed, 27 Oct 2026, of 2 rounds. Its site was last checked 6 Nov 2026: site answers.
Funding
2 rounds on recordRound sizes and total raised are on Fundup AI, our sister product for funding data.
Investors
2 investors on file| Investor | Evidence | Type |
|---|---|---|
| Portfolio page | Venture capital | |
| Page + round | Venture capital |
More from Creandum
35 companies on its checked portfolioIts portfolio leans to AI & Machine Learning (35%), Fintech (19%), Enterprise Software (13%).
More from First Momentum
19 companies on its checked portfolioIts portfolio leans to Industrial & Manufacturing (27%), AI & Machine Learning (18%), Healthcare & Biotech (12%).
See First Momentum's full profile · Who invests alongside it
A company is shown only after its own site answers and carries its name. Sites are checked again on a schedule, because domains lapse and get bought. Round stages and dates come from Fundup AI; investor links come from portfolio pages and rounds; other facts name their source when you point at them. How we grade the data
Get Atlas Bio and its investors as data
Look up any company's investors, or any investor's full portfolio, through one API key or MCP. A free account also opens Ask AI searches and alerts when Creandum adds a company.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/companies/atlas.bio/investors
# also
GET /v1/companies/atlas.bio
GET /v1/companies/atlas.bio/news